Table II.

Pathological characteristics and perioperative outcomes of the overall cohort of patients with clinical stage I-III NSCLC undergoing lobectomy after neoadjuvant chemotherapy vs neoadjuvant immunotherapy.

Characteristics	Chemotherapy (n=4011)	Immunotherapy (n=218)	p-value
Resection approach, no. (%)
Thoracotomy	2511 (62.6%)	86 (39.4%)	<0.0012
VATS	1036 (25.8%)	72 (33.0%)	0.02
Robotic	464 (11.6%)	60 (27.5%)	<0.001
Pathologic T stage, no. (%)
T0/Tis	514 (12.8%)	15 (6.9%)	0.15
T1a	103 (2.6%)	8 (3.7%)
T1b	337 (8.4%)	16 (7.3%)
T1c	456 (11.4%)	29 (13.3%)
T2a	695 (17.3%)	39 (17.9%)
T2b	449 (11.2%)	33 (15.1%)
T3	872 (21.7%)	46 (21.1%)
T4	573 (14.3%)	30 (13.8%)
Unknown	12 (0.3%)	2 (0.9%)
Pathologic N stage, no. (%)
N0	2023 (58.0%)	77 (60.2%)	0.54
N1	583 (16.7%)	25 (19.5%)
N2	870 (25.0%)	26 (20.3%)
N3	11 (0.3%)	0 (0.0%)
Unknown	524	90
Pathologic M stage, no. (%)
M0	1049 (97.9%)	101 (99.0%)	0.43
M1	23 (2.2%)	1 (1.0%)
Unknown	2939	116
Nodal upstaging, no. (%)	275 (7.0%)	16 (7.5%)	0.79
Nodal downstaging, no. (%)	1530 (52.7%)	46 (35.1%)	<0.001
Lymph nodes examined, no. (%)	3896 (97.4%)	211 (96.8%)	0.6
Number of lymph nodes examined (median, IQR)	13.0 (7.0, 21.0)	17.0 (11.0, 28.0)	<0.001
Surgical margin, no. (%)
Negative	3750 (94.2%)	203 (94.4 %)	0.90
Positive	230 (5.8%)	12 (5.6%)
Unknown	31	3
Length of stay (median, IQR)	5.0 (3.0, 7.0)	4.0 (3.0, 6.0)	<0.001
30-day readmission, no. (%)
No	3848 (96.5%)	204 (94.0%)	0.06
Yes	140 (3.5%)	13 (6.0%)
Unknown	23	1
30-day mortality, no. (%)
No	3534 (98.2%)	108 (98.2)	0.99
Yes	66 (1.8%)	2 (1.8%)
Unknown	411	108
90-day mortality, no. (%)
No	3434 (95.8%)	107 (97.3%)	0.45
Yes	150 (4.2%)	3 (2.7%)
Unknown	427	108